Tzu‐Min Yeh

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani et al. · The Lancet · 2021 · 1.7K citations

Medicine, Hematology, Oncology +17

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

Jesús F. San Miguel, Binod Dhakal, Kwee Yong et al. · New England Journal of Medicine · 2023 · 733 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

Thomas G. Martin, Saad Z. Usmani, Jesús G. Berdeja et al. · Journal of Clinical Oncology · 2022 · 633 citations · Full text

Medicine, Hematology, Immunology +17

Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)

Deepu Madduri, Saad Z. Usmani, Sundar Jagannath et al. · Blood · 2019 · 120 citations

Life Sciences, Hematology, Immunology +16

CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.

Yi Lin, Thomas Martin, Jesús G. Berdeja et al. · Journal of Clinical Oncology · 2023 · 113 citations

Medicine, Oncology, Pharmacology +17